GLP inhalation toxicology studies are at the core of our expertise. 

With more than 12 years of experience, an in-house aerosol lab and a team of skilled scientists and engineers, we have specialized capabilities to help assess the preclinical toxicity effects of your inhaled compound. Studies are designed to identify potential acute to chronic toxicity effects as well as carcinogenicity effects, depending on the study objectives. 

Our studies are conducted in accordance to GLP standards and internationally accepted guidelines. 

We support dose range finding studies and repeated dose toxicity studies to identify acute to chronic and carcinogenicity toxicity effects using various routes of administration that are most suited to your research needs. 

A diverse array of in vitro assay panels may be used for early identification of potential hazards of your test items and are important preliminary screening tools prior to in-vivo assessment. At PMI Research Labs, we have established and validated numerous in-vitro assays to assess viability and mutagenesis of novel chemical entities or biologics. 

High quality in-vivo disease models are available to support your research needs. 

Our range of disease models include emphysema, chronic obstructive pulmonary disease (COPD), cardiovascular disease, cough, pulmonary fibrosis, inflammation, ulcerative colitis and multiple sclerosis. In addition, our team of in vivo scientists are ready to work with you to develop additional models to suit your research objectives.

As a full preclinical contracted service provider, we provide end- to- end laboratory solutions including histological and IHC processing, TK/PK, bioanalytical and analytical services, clinical pathology and SEND data conversion to support every point of your preclinical journey.